**Abstract**

**Objective:** The present study aimed to evaluate the efficacy and tolerability of blonanserin compared with other antipsychotics in the management of patients with schizophrenia.

**Methods:** A systematic review and meta-analysis of randomized controlled trials comparing blonanserin head-to-head with other antipsychotics in schizophrenia were conducted. Embase, PubMed, the Cochrane Library databases, Clinicaltrials.gov, and UMIN were searched up to December 2015. The risk ratio (RR) and standardized mean difference (SMD)±95% confidence intervals (CI) were calculated using random-effects models.

**Results:** Results: Nine studies (total n=1,491) were identified (vs. risperidone \[3 studies, n=775\], vs. haloperidol \[2 studies, n=572\], vs. aripiprazole \[2 studies, n=70\], vs. amisulpride \[1 study, n=56\], and vs. paliperidone \[1 study, n=18\]). Comparing blonanserin with other pooled antipsychotics, there were no significant differences in the Positive and Negative Syndrome Scale (PANSS) total score (p=0.84), PANSS positive (p=0.94), PANSS negative (p=0.24), and PANSS general psychopathology subscale scores (p=0.48), and response rate (p=0.92). However, blonanserin showed greater efficacy in PANSS total and positive subscale scores compared with aripiprazole (SMD=-0.83, CI=-1.36 to -0.30, p=0.002 and SMD=-0.82, CI=-1.35 to -0.28, p=0.003, respectively). No significant differences were found in treatment discontinuation between blonanserin and other pooled antipsychotics (due to any cause: p=0.375, inefficacy: p=0.15, adverse events: p=0.75). Blonanserin was significantly lower risk of hyperprolactinemia (RR=0.64, CI=0.51 to 0.80, p\<0.001) and was associated with significantly less blood prolactin increase (SMD=-0.57, CI=-0.86 to -0.29, p\<0.001) than the other pooled antipsychotics. Blonanserin also caused significantly less fatigue (RR=0.71, CI=0.51 to 0.98, p=0.035) and greater use of antiparkinsonian drugs (RR=1.34, CI=1.12 to 1.62, p=0.002).

**Conclusion:** Our results suggest that blonanserin has a more beneficial effect on total and positive symptoms than aripiprazole and that there are significant differences in the safety profile between blonanserin and other antipsychotics.
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